Bayesian Health vs VisualDx
Only one of these holds an FDA clearance. Bayesian Health's sepsis flagging device cleared as K250680 on April 30, 2026, while a 2020 DermExpert FAQ says VisualDx is not FDA approved and is exempt from regulation. Hospitals that want a cleared sepsis monitor go to Bayesian, on a contract with no public price.
VisualDx is a differential builder for skin findings, sold to individuals, small groups and hospitals. Elite costs $299.99 per year billed annually, groups of two to five and large groups are quoted, and the library holds more than 50,000 clinical images across skin tones. It promises integration with "major EHRs" and names none. Bayesian calls its integration EHR-native and names no EHR list either.
A hospital dermatology service wanting rash comparison gets nothing from a sepsis monitor. A sepsis program gets nothing from an image library, and VisualDx makes no regulatory claim for its AI image analysis. That leaves the FDA clearance as the deciding fact for any sepsis purchase.
Decision support · Reviewed November 1, 2026
Bayesian Health
by Bayesian Health
Sepsis flagging software that monitors EHR data continuously and shows a high-risk flag in the chart. FDA 510(k) cleared April 2026.
VisualDx
by VisualDx · founded 1999
Differential diagnosis builder with 50,000+ clinical images across skin tones and body sites.
When to pick each one
Bayesian Health
- FDA 510(k) K250680, cleared April 2026
- Continuous sepsis monitoring from EHR data
- Hospital contract, no public price
VisualDx
- Elite is $299.99 per year, billed annually
- 50,000+ images matched by skin tone and body site
- Groups of 2 to 5 get quoted pricing
Score
Each row shows points earned of points available under the published rubric.
Bayesian Health
33of 100
VisualDx
48of 100
| Dimension | Bayesian Health | VisualDx | Difference |
|---|---|---|---|
| FDA clearance | 12 / 12 | 0 / 12 | +12 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 5.6 | 0 / 5.6 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 4.8 | 0 / 4.8 | 0 |
| Bidirectional write-back | 0 / 1.2 | 0 / 1.2 | 0 |
| Peer-reviewed papers | 8.4 / 21 | 14.7 / 21 | -6.3 |
| RCT / meta-analysis / systematic review | 0 / 9 | 9 / 9 | -9 |
| Funding & adoption signal | 6 / 12 | 8.4 / 12 | -2.4 |
| Pricing transparency | 1.3 / 2.5 | 2.5 / 2.5 | -1.2 |
| Years in market | 0 / 6 | 6 / 6 | -6 |
Scroll horizontally to see every column.
Pricing
Bayesian Health
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
VisualDx
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Core (education) | n/a | $249.99 | Shown as $39.99 or $20.83 per month, billed annually. Free trial length is not stated. Annual plans that auto-renew have a 30-day grace period for a full refund of the renewed fee. |
| Elite (clinicians) | n/a | $299.99 | Shown as $49.99 or $24.99 per month, billed annually. |
| Groups and Enterprise | n/a | n/a | Contact for pricing, including small groups of 2 to 5 users. |
Evidence
Bayesian Health
FDA decisions
K250680 (opens in new tab)510(k)2026-04-30
Bayesian Health Sepsis Flagging Device
Peer-reviewed
1 PubMed record names Bayesian Health.
VisualDx
FDA decisions
No FDA decision cited in our research as of October 20, 2026.
Peer-reviewed
4 PubMed records name VisualDx.
- Early Perspectives on Utilization of a Clinical Decision Support Tool: A Mixed-Methods Study. (opens in new tab)
- Experiences, challenges and lessons while implementing a clinical decision support system in Botswana. (opens in new tab)
- Racial disparities in skin tone representation of dermatomyositis rashes: a systematic review. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Bayesian Health | VisualDx |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | 1999 |
| HQ | US | US |
Scroll horizontally to see both columns.
Common questions
Open the full decision support comparison
Differential diagnosis, treatment guidance, drug interactions, evidence-grounded Q&A. The CDS landscape ranges from the UpToDate gold standard to physician-only OpenEvidence. We compared what clinicians actually use.